Current filters:


Popular Filters

6750 to 6774 of 7207 results

US Senators Burr and Coburn introduce legislation to reform FDA


US Senators Richard Burr (Republican, North Carolina) and Tom Coburn (Republican, Oklahoma) this week…

BiotechnologyLegalNorth AmericaPharmaceuticalPoliticsRegulation

Daiichi Sankyo and Ranbaxy launch Sevikar in Romania


Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority-owned Indian subsidiary Ranbaxy Laboratories…

Cardio-vascularDaiichi SankyoEuropeGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSevikar

PhRMA welcomes US Congressional support for Pediatric Reauthorization ACT


US trade group Pharmaceutical Research and Manufacturers of America (PhRMA) has welcomed the bipartisan…

LegalNorth AmericaPharmaceuticalRegulation

Roche will not extend its tender offer for Illumina


In view of the apparent re-election of the incumbent directors of Illumina (Nasdaq: ILMN), a leading…

BiotechnologyIlluminaMergers & AcquisitionsPharmaceuticalRoche

Abbott beats forecasts as 1st-qtr sees strong sales and earnings growth


US health care major Abbott Laboratories (NYSE: ABT) pleased investors yesterday, reporting better-than-expected…

Abbott LaboratoriesFinancialPharmaceutical

Health activists call for greater public return on EU health R&D spending and a turn to needs-driven innovation


In a Policy Paper published yesterday, Health Action International (HAI) Europe and the Trans Atlantic…


Bristol-Myers expands hepatitis C accord with Medivir and Janssen


Swedish infectious disease drug developer Medivir AB (OMX: MVIR) said yesterday that its development…

Anti-viralsBristol-Myers SquibbdaclatasvirJanssenJohnson & JohnsonLicensingMedivirPharmaceuticalResearch

Intellect Neuro links with University to test potential Alzheimer's vaccine


US neurological-focused drug developer Intellect Neurosciences (OTCBB: ILNS) has entered into a collaboration…

Intellect NeuroscienceNeurologicalPharmaceuticalResearchVaccines

Johnson & Johnson 1st-qtr earnings up 12.5% but sales flat


US health care giant Johnson & Johnson (NYSE: JNJ) posted first-quarter 2012 financial results in line…

FinancialJohnson & JohnsonPharmaceutical

Towards a robust global framework for conduct and oversight of clinical trials in EU


The European Medicines Agency has published the final reflection paper on ethical and good clinical practice…


NICE turns down Roche breast cancer drug Avastin, citing too many uncertainties


UK drug watchdog the National Institute for Health and Clinical Excellence (NICE), said this morning…


Forest Labs profit plunges as Lexapro loses patent


US drugmaker Forest Laboratories (NYSE: FRX) that reported earnings per share equaled $0.72 in the fourth…

FinancialForest LaboratoriesPharmaceutical

Daiichi Sankyo debuts bone cancer drug Ranmark in Japan


Following National Health Insurance price listing yesterday, Japanese drug major Daiichi Sankyo (TYO:…

AmgenAsia-PacificAstraZenecaBiotechnologyDaiichi SankyodenosumabMarkets & MarketingOncologyPharmaceuticalRanmark

Ground-breaking on new Novo Nordisk plant in Russia


Danish insulin giant Novo Nordisk (NOV: N) broke ground yesterday on a new $100 million plant in Russia…

EuropeFinancialInsulinMarkets & MarketingNovo NordiskPharmaceutical

Drug shortages spur developments in neurometabolic treatments


A prolonged gap in the neurology market following the shutdown of a Genzyme production facility is tempting…

BiotechnologyMarkets & MarketingNeurologicalPharmaceuticalRare diseasesResearch

US social media activity in health care viewed by PwC


Social media is changing the nature of health care interaction, and health organizations that ignore…

Markets & MarketingNorth AmericaPharmaceutical

Merck & Co in potential $1 billion deal for cancer drug candidate vintafolide


US drug giant Merck & Co (NYSE: MRK) has entered into an agreement to develop and commercialize Endocyte's…

BiotechnologyEndocyteetarfolatideLicensingMerck & CoOncologyPharmaceuticalvintafolide

Vanda gains rights to Lilly's NK-1 receptor antagonist


USA-based Vanda Pharmaceuticals (Nasdaq: VNDA) said yesterday that it has acquired an exclusive worldwide…

Eli LillyLicensingNeurologicalPharmaceuticalVanda Pharmaceuticals

No proof of added benefit of Sativex, says German IQWiG


In an early benefit assessment under to the German Act on the Reform of the Market for Medicinal Products…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalPricingRegulationSativex

6750 to 6774 of 7207 results

Back to top